Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
PRGN-3006 by Precigen for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
PRGN-3006 is under clinical development by Precigen and currently in Phase I for Relapsed Acute Myeloid Leukemia. According to GlobalData,...
PRGN-3006 by Precigen for Refractory Acute Myeloid Leukemia: Likelihood of Approval
PRGN-3006 is under clinical development by Precigen and currently in Phase I for Refractory Acute Myeloid Leukemia. According to GlobalData,...
PRGN-2012 by Precigen for Recurrent Respiratory Papillomatosis (Juvenile Laryngeal Papilloma or Laryngeal Papilloma): Likelihood of Approval
PRGN-2012 is under clinical development by Precigen and currently in Phase III for Recurrent Respiratory Papillomatosis (Juvenile Laryngeal Papilloma or...
PRGN-2009 by Precigen for Human Papillomavirus (HPV) Associated Cancer: Likelihood of Approval
PRGN-2009 is under clinical development by Precigen and currently in Phase II for Human Papillomavirus (HPV) Associated Cancer. According to...
PRGN-3006 by Precigen for Chronic Myelomonocytic Leukemia (CMML): Likelihood of Approval
PRGN-3006 is under clinical development by Precigen and currently in Phase I for Chronic Myelomonocytic Leukemia (CMML). According to GlobalData,...
PRGN-3006 by Precigen for Myelodysplastic Syndrome: Likelihood of Approval
PRGN-3006 is under clinical development by Precigen and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData, Phase I...